10th April 2019
22nd March 2019
Baricitinib Induces LDL-C and HDL-C Increases in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials...
Network Meta?Analysis of Tofacitinib versus Biologic Treatments in Moderate?to?Severe Rheumatoid Arthritis Patients...
13th March 2019
04th March 2019
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis...
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study...
28th January 2019
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis...
A Pooled analysis of the Safety of Tofacitinib as Monotherapy or in Combination with Background Conventional Synthetic Disease-Modifying Antirheumatic Drugs in a Phase 3 Rheumatoid Arthritis Population...
11th January 2019
Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib, a Selective JAK1 Inhibitor...
Evaluation of the Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis...
07th January 2019
04th December 2018
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
30th November 2018
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids...
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
16th November 2018
- Dr Alan Kivitz discussing his SYK inhibitor data: 00:00-2:09
- Dr Rebecca Kunder talks about the FIL safety study: 2:10-8:12
- Dr Heather Litman describes real-world immunomodulator data: 8:13-10:55
- Professor Roy Fleischmann analyses BARI rescue data: 10.56-15.02
- Dr Lucia Domínguez-Casas reviewes respiratory infection factors: 15.03-17:00
- Professor Peter Taylor with Dr Amer Mirza discuss JAK inhibitor biomarkers: 17:01-18:57
29th October 2018
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study...
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment...
09th October 2018
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab...
Lipid Profile and Effect of Statin Treatment in Pooled Phase II and Phase III Baricitinib Studies...
03rd October 2018
28th August 2018
Tocilizumab Discontinuation After Attaining Remission in Patients with Rheumatoid Arthritis who were Treated with Tocilizumab Alone or in Combination with Methotrexate...
Two Years of Sarilumab in Patients with Rheumatoid Arthritis and an Inadequate Response to MTX...
24th August 2018
25th July 2018
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (SELECT-NEXT)...
Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory To Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND)...
30th June 2018
Long-term Radiographic and Patient-reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib...
Effects of Baricitinib on Radiographic Progression of Structural Joint Damage at 1 year...
30th May 2018
23rd May 2018
Tofacitinib in Rhuematoid Arthritis: Lack of Early Change in Disease Activity Predicts...
Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3..
27th April 2018
Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: a Cohort Study...
Effect of Filgotinib, a Selective JAK1 Inhibitor, with or without Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes..
29th March 2018
Response to Baricitinib based on Prior Biologic Use in Patients with Refractory Arthritis...
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis...
Worldwide, 3-year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis...
29th March 2018
28th February 2018
28th February 2018
Tofacitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Chinese Patients with Rheumatoid Arthritis: Patient-reported Outcomes...
Radiographic Joint Damage in Early Rheumatoid Arthritis Patients: Comparing Tocilizumab- and Methotrexate-based...
02nd February 2018
29th January 2018
Patient-Reported Outcomes in Newly Diagnosed Early Rheumatoid Arthritis Patients Treated to Target with a Tocilizumab- or Methotrexate-based Strategy...
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including...
21st December 2017
Long-term Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis, Stratified by Number of Previous Treatment Failures with Biologic Agents: Results from the German RABBIT Cohort...
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients...
30th November 2017
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA...
Safety and Efficacy of Baricitinib in Elderly Patients with Rheumatoid Arthritis...
30th October 2017
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program...
Patient-reported Outcomes of Baricitinib in Patients with Rheumatoid Arthritis and...
21st September 2017
Patient-reported Outcomes from a Phase 3 Study of Baricitinib versus...
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis...
21st August 2017
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor...
Analysis of Non-melanoma Skin Cancer across the Tofacitinib ...
25th July 2017
Efficacy and Safety of Tofacitinib Monotherapy...
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib...
26th June 2017
Outcomes of Tumor Necrosis Factor Inhibitor Cycling versus...
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor...
Biologics or Tofacitinib for People with Rheumatoid Arthritis Naïve to Methotrexate...
30th April 2017
EULAR RA Management Task Force, Ann Rheum Dis Published Online First: 06March2017. doi:10.1136/annrheumdis-2016-210715
Winthrop, Nature Reviews Rheumatology 2017;13:234–43
31st March 2017
20th October 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
15th September 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
26th July 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Genovese and Prof. Takeuchi
View our CME Courses
25th February 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. J Zhang and Prof. Y Kaneko
20th January 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Laure Gossec
22nd December 2015
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. V Strand and Prof. C Gabay.
21st October 2015
Prof. Iain McInnes presents the inaugural monthly podcast reviewing papers by Prof. Wei Gao and Prof. Cem Gabay focusing on tofacitinib and tocilizumab respectively.
21st October 2015
Steering Committee chair Prof. Iain McInnes introduces his picks of the most important abstracts presented at ACR 2015.